T
he spate of inquiries following the
recent EURECA publication on hypertonic saline in bronchiolitis(1),
prompts this communi-cation on what works (and does not) in this
condition.
Relevance
Bronchiolitis is diagnosed based on the first (or
sometimes subsequent) episode of wheezing in infants, usually concomitant
with a viral upper respiratory infection(2,3). In the context of our
setting, it is always diagnosed clinically and no viral detection tests
are performed. As it is (i) quite common, (ii) often
frustrating to manage, and (iii) therefore open to a variety of
(usually) futile management strategies, a systematic summary of current
best evidence is relevant.
Another issue while summarizing evidence is, which
outcomes should/could be regarded as relevant. This is important because
different RCTs use different outcome measures, not all of which are
clinically important. Often, dramatic effect-sizes for the ‘less relevant’
outcomes are extrapolated to more important outcomes. Therefore choosing
appropriate outcome measures is paramount. For this EURECA review,
clinically relevant ‘hard outcomes’ considered are (i) admission
rate among out-patients, (ii) duration of hospitalization among
in-patients, (iii) clinical cure (both groups), (iv)
requirement of intensive care and (v) death(though rare); whereas
measures such as improvement in clinical status, oxygenation parameters,
symptom scores, time to improvement, etc are surrogate outcomes, hence
regarded as less important.
The clinical question here is "In infants with
bronchiolitis (population), which treatment(s) (intervention) result in
improved/better/favorable outcome (outcome) compared to placebo/no
intervention (comparison)".
Current Best Evidence
A Cochrane Library search on 31 December 2008 showed 7
Cochrane reviews, two protocols, seven other systematic reviews and 235
clinical trials on bronchiolitis. A search for additional randomized
controlled trials (beyond the respective Cochrane review search dates) was
undertaken in Pubmed and identified 76 citations. From each source of
evidence, data on hard outcomes was extracted, (re)analyzed, critically
appraised and are summarized below and in Table I.
Table 1
Interventions for Bronchiolitis
Inhaled epinephrine: There is no benefit in terms
of admission rate or duration of hospitalization; however subgroup
analysis suggests that epinephrine has some benefit among outpatients; it
has been aptly described as the "least ineffective" intervention(3).
Similarly, there is no difference for surrogate outcomes including change
in oxygen saturation, heart rate and respiratory rate, although
epinephrine results in more favourable clinical score change from
baseline.
Inhaled bronchodilators: There is no
benefit of inhaled salbutamol for admission rate or duration of
hospitalization. However, clinical score appears to be better with
salbutamol, although another surrogate outcome (oxygenation) shows no
difference.
Inhaled epinephrine vs inhaled bronchodilator:
There is no difference in admission rate or duration of hospitalization,
though subgroup analysis shows marginal benefit among outpatients. Change
in clinical score at serial intervals, oxygenation parameters, serial
measurements of heart rate and respiratory rate, also are not different
between the groups. As both interventions show no difference when compared
to placebo, it follows that neither is superior.
Inhaled anticholinergics: Compared to placebo,
ipratropium does not show any benefit in admission rate, duration of
hospitalization and also most surrogate outcomes (clinical improvement,
oxygenation parameters, symptom score), except parental assessment of
improvement. A combination of ipratropium with salbutamol (vs salbutamol
alone) also does not show any benefit for various surrogate outcomes.
Glucocorticoids: This is no difference from
placebo for hard outcomes and several surrogate outcomes (clinical scores,
oxygenation parameters, respiratory rate, readmission rate). One recent
RCT shows that a single dose of intravenous dexamethasone results in
(statistically but not clinically significant) shorter duration of
hospitalization and time for resolution of respiratory distress(13).
Inhaled dexamethasone does not show any difference in clinical score and
oxygenation compared to saline(18).
Hypertonic saline nebulization: Although the
admission rate is no different compared to placebo, the duration of
hospitalization is less by almost one day with hypertonic saline
nebulisation. Clinical severity scores show variable results for
inpatients and outpatients, on different days of measurement, but are
mostly in favour of hypertonic saline. The limitations with hypertonic
saline have been presented previously(1).
Surfactant: Surfactant does not reduce the
duration of hospitalization, but results in shorter duration of ICU stay
despite no significant reduction in the duration of ventilation.
Antibiotics: Clarithromycin decreases the duration
of hospitalization as compared to placebo, but the single RCT showing this
finding administered the antibiotic for three weeks(15). The Cochrane
review on antibiotics included only one RCT on ampicillin versus placebo,
but did not report any event in either arm(19).
Chest physiotherapy: This does not reduce the
duration of hospitalization and there is no data on admission rate.
Other interventions: Two RCTs (n=140,
n=129) on oral salbutamol versus placebo show that there is no
difference in terms of clinical recovery/cure(20,21). One RCT on nasal
phenylephrine versus placebo (n=41) shows that there is no
significant difference for outcomes such as oxygenation and clinical
score(22). Similarly, inhaled furosemide is no different from placebo in
terms of oxygenation parameters(23). One RCT comparing inhaled salbutamol
with dexamethasone versus salbutamol alone shows that both are comparable
for various measures such as heart rate, respiratory rate respiratory
distress scores and oxygenation(24). Montelukast does not reduce duration
of hospitalization and measures such as clinical severity scores(17).
There is no RCT comparing steam inhalation versus no inhalation.
Interventions that are not available in India (heliox, ribavarin,
vaccination) have not been considered in this review.
Critical Appraisal
Despite the widespread use of various interventions
(singly and in combination) among infants with bronchiolitis, robust data
represented by systematic reviews and RCTs are lacking in quantity and
quality. Most trials highlight results showing superiority of intervention
(compared to placebo) for a variety of outcomes that are not of high
clinical priority; on the other hand limited data for clinically relevant
(hard) outcomes do not speak in favour of any of the interventions. Many
trials (and even systematic reviews) are under-powered (small sample
size), leading to the disappointing conclusion that more research is
required for most interventions. It should be noted that there is no
robust evidence even for the so-called recommended standard treatment
(oxygen and fluids) in bronchiolitis(2,3,25).
Extendibility
An important issue in extending evidence from the
research setting to the bedside, is whether ‘bronchiolitis’ defined in
various RCTs (and systematic reviews) matches our perception of the
condition. Fortunately, this is not a problem as most RCTs included
infants with a clinical diagnosis of bronchiolitis (almost exactly as we
would in the local setting), very few included viral studies to confirm
the presence of the usual causal viruses and almost none used less
well-defined terminology such as ‘viral wheeze’ etc. In addition, many
RCTs included infants prior to hospital admission (outpatients) and very
few were conducted in the setting of an intensive care unit. Thus,
although most trials were not conducted in developing countries, the
inclusion criteria were similar to those routinely used. Therefore the
evidence can be extended to our setting.
Competing interest: None stated.
Funding: None.
EURECA Conclusions in the Indian Context
• None of the interventions commonly used in
bronchiolitis is backed by robust evidence of benefit for clinically
significant outcomes. |
References
1. Mathew JL. Hypertonic saline nebulization for
bronchiolitis. Indian Pediatr 2008; 45: 987-989.
2. Worrall G. Bronchiolitis. Can Fam Phy 2008; 54:
742-743.
3. Bush A, Thomson AH. Acute bronchiolitis. BMJ 2007;
335: 1037-1041.
4. Hartling L, Wiebe N, Russell K, Patel H, Klassen TP.
Epinephrine for bronchiolitis. Cochrane Database Syst Rev 2004; 1:
CD003123.
5. Ralston S, Hartenberger C, Anaya T, Qualls C, Kelly
HW. Randomized, placebo-controlled trial of albuterol and epinephrine at
equipotent beta-2 agonist doses in acute bronchiolitis. Pediatr Pulmonol
2005; 40: 292-299.
6. Mull CC, Scarfone RJ, Ferri LR, Carlin T, Salvaggio
C, Bechtel KA, et al. A randomized trial of nebulized epinephrine
vs albuterol in the emergency department treatment of bronchiolitis. Arch
Pediatr Adolesc Med 2004; 158: 113-118.
7. Gadomski AM, Bhasale AL. Bronchodilators for
bronchiolitis. Cochrane Database Syst Rev 2006, 3: CD001266.
8. Everard M, Bara A, Kurian M, N’Diaye T, Ducharme F,
Mayowe V. Anticholinergic drugs for wheeze in children under the age of
two years. Cochrane Database Syst Rev 2005; 3: CD001279.
9. Patel H, Platt R, Lozano JM, Wang EE.
Glucocorticoids for acute viral bronchiolitis in infants and young
children. Cochrane Database Syst Rev 2004; 3: CD004878.
10. Corneli HM, Zorc JJ, Mahajan P, Shaw KN, Holubkov
R, Reeves SD, et al. A multicenter, randomized, controlled trial of
dexamethasone for bronchiolitis. N Engl J Med 2007; 357: 331-339.
11. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen
TP. Nebulized hypertonic saline solution for acute bronchiolitis in
infants. Cochrane Database Syst Rev 2008; 4: CD006458.
12. Langley JM, Smith MB, LeBlanc JC, Joudrey H, Ojah
CR, Pianosi P. Racemic epinephrine compared to salbutamol in hospitalized
young children with bronchiolitis; a randomized controlled clinical trial.
BMC Pediatr 2005; 5: 7-10.
13. Teeratakulpisarn J, Limwattananon C,
Tanupatta-rachai S, Limwattananon S, Teeratakulpisarn S, Kosalaraksa P.
Efficacy of dexamethasone injection for acute bronchiolitis in
hospitalized children: a randomized, double-blind, placebo-controlled
trial. Pediatr Pulmonol 2007; 42: 433-439.
14. Ventre K, Haroon M, Davison C. Surfactant therapy
for bronchiolitis in critically ill infants. Cochrane Database Syst Rev
2006; 3: CD005150.
15. Tahan F, Ozcan A, Koc N. Clarithromycin in the
treatment of RSV bronchiolitis: a double-blind, randomised,
placebo-controlled trial. Eur Respir J 2007; 29: 91-97.
16. Perrotta C, Ortiz Z, Roqué Figuls M. Chest
physiotherapy for acute bronchiolitis in paediatric patients between 0 and
24 months old. Cochrane Database Syst Rev 2007; 1: CD004873.
17. Amirav I, Luder AS, Kruger N, Borovitch Y, Babai I,
Miron D, et al. A double-blind, placebo-controlled, randomized
trial of montelukast for acute bronchiolitis. Pediatrics 2008; 122:
e1249-1255.
18. Bentur L, Shoseyov D, Feigenbaum D, Gorichovsky Y,
Bibi H. Dexamethasone inhalations in RSV bronchiolitis: a double-blind,
placebo-controlled study. Acta Paediatr 2005; 94: 866-871.
19. Spurling GKP, Fonseka K, Doust J, DelMar C.
Antibiotics for bronchiolitis in children. Cochrane Database Syst Rev
2007; 1: CD005189.
20. Gupta P, Aggarwal A, Gupta P, Sharma KK. Oral
salbutamol for symptomatic relief in mild bronchiolitis a double blind
randomized placebo controlled trial. Indian Pediatr 2008 ; 45: 547-553.
21. Patel H, Gouin S, Platt RW. Randomized,
double-blind, placebo-controlled trial of oral albuterol in infants with
mild-to-moderate acute viral bronchiolitis. J Pediatr 2003; 142: 509-514.
22. Ralston S, Roohi M. A randomized, controlled trial
of nasal phenylephrine in infants hospitalized for bronchiolitis. J
Pediatr 2008; 153: 795-798.
23. Bar A, Srugo I, Amirav I, Tzverling C, Naftali G,
Kugelman A. Inhaled furosemide in hospitalized infants with viral
bronchiolitis: a randomized, double-blind, placebo-controlled pilot study.
Pediatr Pulmonol 2008; 43: 261-267.
24. Gómez-y-López RE, Hernández-Sierra JF,
Torres-Ruvalcaba BA, Martínez-Puente E, del Carmen Martínez-Garcia M.
Comparative clinical study of dexamethasone vs. nebulized salbutamol in
acute bronchiolitis. Gac Med Mex 2007; 143: 189-192.
25. Thia LP, McKenzie SA, Blyth TP, Minasian CC, Kozlowska WJ, Carr SB.
Randomised controlled trial of nasal continuous positive airways pressure
(CPAP) in bronchiolitis. Arch Dis Child. 2008; 93: 45-47.